Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Trials
Collaboration
Funding
Sbir Grant
SLAS 2022: 6 tips for scientists looking to start companies
1. Find the right team
February 8, 2022
BioMarker Strategies advances immunotherapy test through SBIR grant
The contract runs for two years and covers use of the test for predicting response to treatments given alone or in combination to patients with non-small cell lung cancer (NSCLC). This represents the second phase of immunotherapy response test development for the NCI; in the first phase, BioMarker Strategies established proof of concept. Immunotherapies have revolutionized the treatment of several cancer types, but there is a strong need for better ways of identifying patients who benefit, as the objective response rates for PD-1/PD-L1 inhibitors are low, ranging from 10% to 30%.
January 6, 2020
Startup develops POC diagnostic for tuberculosis
The platform is initially intended for use in South Africa. Eventually, the technology could be applied to detect other organisms responsible for conditions in other geographies.
December 8, 2019
Most Popular
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
Cue Health Q4 revenues decline 24% as firm expands, diversifies POC test menu
Page 1 of 1
